Indian pharma has bounced back from lockdown lows. What led to turnaround?

From the lows of the lockdown, the industry has seen a robust bounceback

The domestic pharma market has not only recovered from the lows of the lockdown-hit months of April-June, but is likely to do better in the second half of the fiscal.

Pandemic blues seem to be a thing of the past as the domestic drug market showed resilience in the last three months, maintaining a growth momentum. In October, the Indian pharma market (IPM) clocked a strong 9.6 per cent growth after growing 4.5 per cent in September and 2.2 per cent in August.

Compare this with the lockdown-hit months when the IPM volume growth was down 17 per cent in April and